Pharmaceutical company Merck, which makes Levothyrox, was ordered to make the payments by the Court of Appeal in Lyon.
Lawyer for the patients, Christophe Lèguevaques, announced this week (June 25) that the court had recognised that Merck committed “an error” when changing its treatment, and had ordered the company to pay €1,000 to each of the plaintiffs - a bill amounting to more than €3 million for the US-based firm.
He said: “The court considers that there was a moral injury suffered by all parties."
The case in Lyon, which was first brought by more than 4,000 patients, was initially thrown out after judges said Merck had no case to answer on the launch of its “new formula” of Levothyrox in 2017.
After this, around 800 patients dropped the case, but the remaining 3,329 patients brought an appeal, maintaining that they had suffered side-effects and serious medical issues due to the change in the formula.
They had initially claimed 10,000 in compensation each - which would have amounted to a bill of €33 million in total for Merck.
Controversy erupted over the medication in summer 2017, after Merck launched a “new formula” of the drug. Thousands of patients claimed that they had seen a return of negative symptoms after taking the new drug, and some even alleged that their thyroid cancers had returned due to the new drug not working as effectively as the old one.
More than one death has also been associated with the case, seeing an allegation of manslaughter brought against Merck.
In October 2017, then-French health minister Agnes Buzyn ordered 130,000 boxes of the old formula nationwide, half of which sold out within two days, and a helpline number was set up for patients.
Patient advocate groups launched multiple court cases against the manufacturer.
But Merck has always maintained that its new formula is “bioequivalent (medically identical)” to the old one, and that only non-active ingredients of the drug were changed, to conform to new medication rules from medical safety agency l'Agence Nationale de Sécurité du Médicament (ANSM).
ANSM itself conducted its own independent analysis of the drug and found it to be “good quality”.
A later, separate, French-UK study found that the drug was in fact “not equivalent”, and concluded that 60% of patients prescribed the drugs “may not react” in the same way to both formulas, and that the new medicine may not be equally absorbed by everyone.
New France-UK study finds Levothyrox ‘not equivalent’
French senator calls for new inquiry into Levothyrox
French agency confirms ‘good quality’ of Levothyrox
Calls for health minister to go amid new thyroid study
Sign up to our free weekly e-newsletter
Subscribe to access all our online articles and receive our printed monthly newspaper The Connexion at your home. News analysis, features and practical help for English-speakers in France